Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum; Fabian Schmidt; Fengwen Zhang; Justin DaSilva; Daniel Poston; Julio C C Lorenzi; Frauke Muecksch; Magdalena Rutkowska; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Larry Luchsinger; Christopher D Hillyer; Marina Caskey; Davide F Robbiani; Charles Rice; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-214759

Documentos relacionados

  1. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
  2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
  3. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
  4. High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.
  5. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
  6. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
  7. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  8. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
  9. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
  10. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.